For the quarter ended March 2025, Labcorp (LH) reported revenue of $3.35 billion, up 5.3% over the same period last year. EPS came in at $3.84, compared to $3.68 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $3.41 billion, representing a surprise of -2.04%. The company delivered an EPS surprise of +2.95%, with the consensus EPS estimate being $3.73.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compa ...

Core Insights - Paypal reported $7.79 billion in revenue for Q1 2025, a year-over-year increase of 1.2%, with an EPS of $1.33 compared to $1.40 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $7.81 billion, resulting in a surprise of -0.23%, while the EPS exceeded expectations by +15.65% [1] Financial Performance Metrics - Transaction take rate remained stable at 1.7%, matching analyst estimates [4] - Total Payment Volume (TPV) was $417.21 billion, slightly below the estimated $420.67 billion [4] - Total take rate was reported at 1.9%, in line with analyst expectations [4] - Transaction margin improved to 47.7%, exceeding the estimated 46.5% [4] - Transaction expense rate was consistent at 0.9%, matching analyst estimates [4] - Active accounts reached 436 million, slightly above the estimated 435 million [4] - Transaction and credit loss rate was stable at 0.1%, aligning with analyst expectations [4] - The number of payment transactions was 6,045, lower than the estimated 6,676 [4] - Revenues from other value-added services were $775 million, surpassing the average estimate of $667.22 million, representing a year-over-year increase of +16.5% [4] - Transaction revenues totaled $7.02 billion, which is a -0.3% change compared to the previous year and below the estimated $7.17 billion [4] Stock Performance - Over the past month, Paypal shares returned -0.5%, compared to the Zacks S&P 500 composite's -0.8% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market [3]

Core Earnings and Revenue Performance - AstraZeneca's first-quarter 2025 core earnings were $1.24 per American depositary share (ADS), exceeding the Zacks Consensus Estimate of $1.10, with core earnings of $2.49 per share reflecting a 21% year-over-year increase at constant exchange rates (CER) [1][2] - Total revenues reached $13.59 billion, a 7% increase on a reported basis and 10% at CER, although this figure fell short of the Zacks Consensus Estimate of $13.68 billion [2] Product Sales and Therapeutic Areas - Product sales increased by 9% to $12.88 billion, driven by strong demand for marketed products [3] - Oncology product sales rose 13%, while Cardiovascular, Renal and Metabolism (CVRM) product sales increased by 12%, and Respiratory & Immunology (R&I) segment sales grew by 11%. However, sales in the Rare Disease segment remained flat, and Vaccines & Immune (V&I) Therapies saw a decline of 30% [4] Collaboration Revenues - Collaboration revenues totaled $74 million, a 64% increase attributed to a sales milestone for Farxiga in Japan, while alliance revenues rose 42% to $639 million, driven by growth from partnered medicines [5][6] Key Drug Performance - Tagrisso sales reached $1.68 billion, up 8%, surpassing estimates [7] - Lynparza sales increased by 5% to $726 million but missed estimates due to soft performance in emerging markets and U.S. headwinds [8][9] - Imfinzi generated $1.26 billion in sales, up 16%, but also missed estimates [9] - Calquence sales rose 8% to $762 million, beating estimates [10] - New drug Truqap recorded $132 million in revenues, down from the previous quarter due to Medicare Part D redesign impacts [11] Segment Performance - In the CVRM segment, Farxiga sales were $2.06 billion, up 16%, benefiting from label expansions [12] - Brilinta/Brilique sales decreased by 4% to $305 million, while new drug Wainua added $39 million in sales [13] - In the R&I segment, Symbicort sales declined by 3% to $723 million, and Pulmicort sales fell by 26% [14] - Fasenra recorded a 19% increase in sales to $418 million, exceeding estimates [15] - In the Rare Disease portfolio, Soliris sales fell 38% to $444 million, while Ultomiris revenues rose 25% to $1.05 billion [17] Cost and Guidance - Core selling, general and administrative expenses increased by 4% to $3.46 billion, while core research and development expenses rose 16% to $3.09 billion [19] - AstraZeneca maintained its 2025 guidance, expecting total revenues to grow by a high single-digit percentage at CER and core EPS to increase by a low double-digit percentage [20] Strategic Updates - AstraZeneca announced the discontinuation of the CAPItello-280 study for Truqap in metastatic castration-resistant prostate cancer [22] - The company received a positive recommendation for a label expansion involving Calquence for CLL treatment [23] - AstraZeneca plans to launch 20 new medicines by 2030, targeting $80 billion in total annual revenues by the end of the decade [29]

Core Insights - Tesla's earnings report provides insights into the company's strategies for managing significant near-term challenges [1] Financial Performance - The report highlights Tesla's financial performance amidst market fluctuations and operational hurdles [1] Market Response - Stock prices referenced were from the afternoon of April 23, 2025, indicating market reactions to the earnings report [1]

Pfizer Inc. PFE will release earnings results for the first quarter, before the opening bell on Tuesday, April 29. Analysts expect the New York-based company to report quarterly earnings at 68 cents per share, down from 82 cents per share in the year-ago period. Pfizer projects to report quarterly revenue at $14.09 billion, compared to $14.88 billion a year earlier, according to data from Benzinga Pro. Guardant Health GH, on April 24, announced a strategic collaboration with Pfizer to support the developmen ...

Core Insights - CNO Financial reported a revenue of $1.01 billion for Q1 2025, reflecting a year-over-year decline of 12.6% while EPS increased to $0.79 from $0.52 a year ago, exceeding the Zacks Consensus Estimate of $961.36 million by 5.15% [1] Group 1: Financial Performance - The reported insurance policy income was $650.70 million, slightly below the average estimate of $651.36 million, marking a year-over-year increase of 3.6% [4] - The Insurance Product Margin for Annuity was reported at $54.50 million, lower than the estimated $60.39 million [4] - The Insurance Product Margin for Life was $68.20 million, surpassing the average estimate of $52.37 million [4] - The Insurance Product Margin for Health was $126.20 million, slightly below the average estimate of $127.96 million [4] Group 2: Stock Performance - CNO shares have returned -4.6% over the past month, compared to a -4.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Group 1 - Two Harbors Investments reported a revenue of $-20.33 million for the quarter ended March 2025, representing a decline of 51.8% compared to the same period last year [1] - The company's earnings per share (EPS) for the quarter was $0.24, an increase from $0.05 in the year-ago quarter [1]

Core Insights - Merchants Bancorp reported a revenue of $145.89 million for the quarter ended March 2025, reflecting a 13.1% decline year-over-year and falling short of the Zacks Consensus Estimate of $167.04 million by 12.66% [1] - The company's earnings per share (EPS) was $0.93, down from $1.80 in the same quarter last year, and also below the consensus estimate of $1.25, resulting in an EPS surprise of -25.60% [1] Financial Performance Metrics - Efficiency Ratio was reported at 42.3%, higher than the three-analyst average estimate of 38% [4] - Net interest margin stood at 2.9%, slightly below the estimated 3% by three analysts [4] - Average Earning Assets were $17.14 billion, lower than the average estimate of $18.15 billion [4] - Tier I capital/risk-weighted assets Ratio was 12.4%, exceeding the two-analyst average estimate of 12% [4] - Total capital/risk-weighted assets Ratio was 13%, slightly above the estimated 12.9% by two analysts [4] - Loan servicing fees (costs), net, were $4.01 million, higher than the average estimate of $3.17 million [4] - Syndication and asset management fees were $3.39 million, below the average estimate of $5.08 million [4] - Other income was reported at $3.16 million, compared to the average estimate of $4.80 million [4] - Mortgage warehouse fees were $1.51 million, exceeding the average estimate of $1.24 million [4] - Total Noninterest Income was $23.69 million, significantly lower than the average estimate of $34.95 million [4] - Gain on Sale of Loans was $11.62 million, compared to the average estimate of $20.67 million [4] - Net Interest Income was reported at $122.20 million, below the average estimate of $132.11 million [4] Stock Performance - Shares of Merchants Bancorp have declined by 12.4% over the past month, while the Zacks S&P 500 composite decreased by 4.3% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - UFP Industries (UFPI) reported $1.6 billion in revenue for Q1 2025, a year-over-year decline of 2.7% and an EPS of $1.30 compared to $1.96 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $1.63 billion by 2.19%, and the EPS was 18.24% below the consensus estimate of $1.59 [1] Revenue Performance - Retail net sales were $607.38 million, below the estimated $644.47 million, reflecting a year-over-year decline of 3.4% [4] - Construction net sales reached $515.94 million, slightly above the average estimate of $508.43 million, showing a minimal decline of 0.4% year over year [4] - Packaging net sales were reported at $410.01 million, exceeding the estimated $405.32 million, with a year-over-year decline of 3.4% [4] Stock Performance - UFP Industries' shares returned +0.4% over the past month, contrasting with the Zacks S&P 500 composite's decline of -4.3% [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Insights - Universal Health Services (UHS) reported revenue of $4.1 billion for the quarter ended March 2025, reflecting a year-over-year increase of 6.7% [1] - Earnings per share (EPS) for the quarter was $4.84, up from $3.70 in the same quarter last year, resulting in an EPS surprise of +11.01% against the consensus estimate of $4.36 [1] - The reported revenue was slightly below the Zacks Consensus Estimate of $4.14 billion, showing a surprise of -1.06% [1] Financial Performance Metrics - Behavioral health admissions totaled 117,788, which was below the two-analyst average estimate of 122,821 [4] - Net revenues from behavioral health services were reported at $1.75 billion, compared to the average estimate of $1.79 billion, marking a year-over-year increase of +5.5% [4] - Net revenues from acute care hospital services matched the average estimate of $2.35 billion, representing a +7.5% change from the previous year [4] - Operating income for behavioral health care services was $337.68 million, slightly below the three-analyst average estimate of $346.29 million [4] - Operating income for acute care hospital services was reported at $254.79 million, exceeding the average estimate of $206.21 million [4] Stock Performance - Shares of Universal Health Services have returned -7.8% over the past month, compared to a -4.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 1 (Strong Buy), indicating potential for outperformance in the near term [3]